Ascendent Capital
Asia value creation: Internal repairs
Private equity investors in Asia are responding to an increasingly competitive deal-sourcing environment with a stronger focus on value-add, but successful implementation will require a cultural commitment
Ascendent backs China cancer diagnostics firm
Ascendent Capital Partners has committed RMB50 million ($7.36 million) to BioChain Beijing, a Chinese biotech company that focuses on early detection of cancer.
Ascendent supports buyout of HK-listed China Automation
Ascendent Capital Partners has teamed up with the chairman and founder of China Automation Group to invest HK$549.5 million ($70.8 million) in the Hong Kong-listed company, triggering a mandatory buyout offer.
China GPs underline merits of sector focus
China GPs must respond to the country’s economic slowdown by paying closer attention to picking sectors that can outperform – and in which they can help drive that performance – industry participants told the Hong Kong Venture Capital & Private...
Ascendent sees 5x return on China high-speed rail investment
Ascendent Capital Partners has completed its exit from Nano Resources, a components manufacturer for high-speed trains, generating a more than 5x return.
AVCJ Awards 2015: Fundraising of the Year - Mid Cap: Ascendent Capital Partners
As corporate China adjusts to a slower growth environment, Ascendent Capital Partners’ strategy of providing advice alongside capital resonated with LPs
The long game: Merchant banking-style PE
Ascendent Capital Partners’ China strategy involves advising companies first and raising the prospect of investment second, perhaps with a sizeable gap in between. Does this signal change in the middle market?
Ascendent closes second China fund at $600m hard cap
Ascendent Capital Partners has reached a first and final close on its second China fund at the hard cap of $600 million. The vehicle has been in the market for around four months, following an official launch in March.
China middle market: Filling the void
A clutch of China GPs now manage funds of $1 billion or more, leaving the traditional middle market space underserved. Those that remain must convince LPs they can deal with a changing opportunity set
Ascendent seeks $500m for second China fund
China-focused GP Ascendent Capital Partners has set a target of $500 million for its second fund.
China downside protection: Parachute play
All PE investors want downside protection in China, but they prefer to use it as leverage in amicable negotiations rather than pursue full enforcement. Knowing the entrepreneur and the business is crucial